Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 23, 2021 at 02:56 pm
Share
Adhera Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 129,000 compared to USD 356,000 a year ago. Net loss was USD 514,000 compared to USD 906,000 a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.12 a year ago. For the half year, operating loss was USD 239,000 compared to USD 1.679 million a year ago. Net loss was USD 942,000 compared to USD 2.744 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.32 a year ago.
Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Companyâs behalf and under its direct supervision.
ADHERA THERAPEUTICS, INC. 
